ライフサイエンスコーパス: radioactive iodine

1 when used either unconjugated or attached to radioactive iodine.

2 O prostate cancer patients were treated with radioactive iodine 125 (125I) prostate implants followed

3 e tumor immediately before implantation of a radioactive iodine 125 plaque as treatment for the tumor

4 The use of radioactive iodine ((131)I) for the treatment of thyroid

5 le thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactor

6 Patients with radioactive iodine ((131)I)-refractory locally advanced

7 n after exposure to low or moderate doses of radioactive iodine-131 (131I) at a young age is a public

8 role in the treatment of thyroid diseases by radioactive iodine 131I.

9 well-differentiated thyroid cancer receiving radioactive iodine (1373/3397 [40.4%] vs 11,539/20,620 [

10 tomy and central neck dissection followed by radioactive iodine ablation and thyroid hormone suppress

11 possible lymphadenectomy, and postoperative radioactive iodine administration.

12 ntiated thyroid cancer patients treated with radioactive iodine after total thyroidectomy was assesse

13 Use of radioactive iodine after total thyroidectomy.

14 f developing a single agent that can deliver radioactive iodine and also direct cellular immune funct

15 tatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAF(V600E) muta

16 iate-risk disease, for which use of adjuvant radioactive iodine and surveillance intensity are not cu

17 prophylactic central neck dissection, use of radioactive iodine, and degree of thyrotropin suppressio

18 Antithyroid drugs, radioactive iodine, and surgery are the traditional trea

19 During nuclear waste disposal process, radioactive iodine as a fission product can be released.

20 e determination of aqueous concentrations of radioactive iodine as I2, I(-), and IO3(-).

21 In conclusion, persons exposed to radioactive iodines as children and adolescents have an

22 was an increase in the proportion receiving radioactive iodine between 1990 and 2008; much of the va

23 g zeolites may offer a more secure route for radioactive iodine capture, with the potential to more e

24 e the strengths of the hybrid by considering radioactive iodine capture.

25 accident in 1986 exposed many individuals to radioactive iodines, chiefly (131)I, the effects of whic

26 ancer in children and adolescents exposed to radioactive iodines, chiefly iodine-131 ((131)I), after

27 cularly the extent of lymph-node dissection, radioactive iodine dosing, and the role of genetic analy

28 local recurrence and may alter postsurgical radioactive iodine dosing.

29 ar cell to take up iodine permits the use of radioactive iodine for follow-up and therapy.

30 of diagnosis, followed by administration of radioactive iodine for remnant ablation.

31 ssociated with greater hospital-level use of radioactive iodine for stage I disease.

32 resection is associated with greater use of radioactive iodine for stage I thyroid cancer.

33 resection is associated with greater use of radioactive iodine for stage I thyroid cancer.

34 certainty persists about the indications for radioactive iodine for thyroid cancer.

35 localization in 2 patients and placement of radioactive iodine I 125 (125I)-labeled seeds in 10 pati

36 cedure [marking the axillary lymph node with radioactive iodine (I) seeds] is a new minimal invasive

37 They were also more likely to favor radioactive iodine in patients with intrathyroidal unifo

38 the first time, the speciation of stable and radioactive iodine in the groundwater from the Hanford S

39 atment of differentiated thyroid cancer with radioactive iodine is associated with a small increase i

40 Although radioactive iodine is effective, its appropriate use and

41 Radioactive iodine is of little use.

42 molecular tag was introduced in the form of radioactive iodine or biotin.

43 andard treatment (surgery followed by either radioactive iodine or observation) is effective.

44 Use of radioactive iodine over time and the correlates of its u

45 rbidity in thyroid cancer patients receiving radioactive iodine (RAI) for remnant ablation or therapy

46 though surgery is the mainstay of treatment, radioactive iodine (RAI) is routinely used for adjuvant

47 Decision-making on adjuvant radioactive iodine (RAI) treatment for early-stage papil

48 The optimal management of radioactive iodine (RAI) treatment in patients with meta

49 sease may be treated with antithyroid drugs, radioactive iodine (RAI), or surgery (near-total thyroid

50 ed thyroid cancer (WDTC) treated or not with radioactive iodine (RAI).

51 y) were treated with (131)I (radioiodine, or radioactive iodine [RAI]); the median follow-up was 10 y

52 PDTC), anaplastic thyroid cancers (ATC), and radioactive iodine-refractory (RAIR) differentiated thyr

53 ed with placebo in patients with progressive radioactive iodine-refractory differentiated thyroid can

54 eatment option for patients with progressive radioactive iodine-refractory differentiated thyroid can

55 Food and Drug Administration for metastatic, radioactive iodine-refractory differentiated thyroid can

56 (400 mg orally twice daily) in patients with radioactive iodine-refractory locally advanced or metast

57 tent of resection and medical treatment with radioactive iodine remains unknown.

58 d stimulating hormone (rhTSH) for (1)(3)(1)I radioactive iodine remnant ablation in patients with low

59 Recent studies have confirmed that radioactive iodine therapy after recombinant human TSH (

60 HR, 0.26 [95% CI, 0.12-0.51]) compared with radioactive iodine therapy alone.

61 s may reassure patients about the effects of radioactive iodine therapy on fertility, although men ma

62 Impact of radioactive iodine therapy on subsequent fertility has b

63 r Graves' disease include antithyroid drugs, radioactive iodine therapy, and surgery, whereas antithy

64 , histology, presence of distant metastasis, radioactive iodine trapping ability, adjuvant treatment,

65 including prophylactic CLND and avoidance of radioactive iodine treatment for DTC, when appropriate.

66 ifocality, nodal and distant metastases, and radioactive iodine treatment.

67 bulinemia and may modify the indications for radioactive iodine treatment.

68 patients had low thyroid hormone levels and radioactive iodine uptake in the thyroid gland associate

69 d that there was a statistical difference in radioactive iodine use between American Joint Committee

70 Wide variation in radioactive iodine use existed, and only 21.1% of this v

71 ETTING, AND PATIENTS: Time trend analysis of radioactive iodine use in a cohort of 189,219 patients w

72 s of patient and hospital characteristics on radioactive iodine use in the cohort treated from 2004 t

73 ristics, hospital volume was associated with radioactive iodine use.

74 dy of Graves hyperthyroidism, treatment with radioactive iodine was more likely than methimazole ther

75 Radioactive iodine was not linked to total cancer deaths

76 itive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a mul